Streetbeat News

Analyst Ratings

FRSH

Morgan Stanley analyst Elizabeth Porter has maintained an Equal-Weight rating on Freshworks (NASDAQ:FRSH) and lowered the price target from $24 to $22.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:43 pm

FOXA

Morgan Stanley analyst Benjamin Swinburne has maintained an Equal-Weight rating on Fox (NASDAQ:FOXA), but lowered the price target from $39 to $35.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:41 pm

UFPI

DA Davidson analyst Kurt Yinger has downgraded UFP Industries (NASDAQ:UFPI) from Buy to Neutral and lowered the price target from $122 to $106.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:41 pm

AMD

Advanced Micro Devices (AMD) shares are trading lower following the company's Q3 financial results. Despite beating revenue and EPS estimates, multiple analysts lowered price targets. Data center revenue was flat YoY, client revenue was up 42% YoY, gaming revenue was down 8% YoY, and embedded revenue was down 5% YoY. AMD expects Q4 revenue of approximately $6.1 billion, representing growth of about 9% at the midpoint.

Portfolio Pulse from Adam Eckert

November 01, 2023 | 12:41 pm

EQH

Morgan Stanley analyst Nigel Dally has maintained an Overweight rating on Equitable Hldgs (NYSE:EQH) but lowered the price target from $40 to $38.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:41 pm

ARGX

Morgan Stanley analyst Matthew Harrison maintains an Overweight rating on argenx (NASDAQ:ARGX) and raises the price target from $604 to $607.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:39 pm

XPOF

B of A Securities analyst Alexander Perry has downgraded Xponential Fitness (NYSE:XPOF) from Buy to Neutral and lowered the price target from $35 to $16.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:39 pm

PAYC

Stifel analyst Brad Reback has downgraded Paycom Software (NYSE:PAYC) from Buy to Hold and lowered the price target from $400 to $160.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:37 pm

LEXX

Lexaria Bioscience Corp. (NASDAQ:LEXX) is expanding its studies of its proprietary DehydraTECH platform in the GLP-1 drug space, a market estimated to reach $82.93 billion by 2027. The company's early studies in 2022 showed positive effects of lowering glucose levels, body weight, and triglyceride levels, and increased locomotor activity.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:31 pm

STVN

Jefferies analyst David Windley has downgraded Stevanato Gr (NYSE:STVN) from Buy to Hold and lowered the price target from $39 to $29.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 12:29 pm